CAR T cells engineered to secrete tumor-localized anti-EpCAM bispecific T cell engagers (BTCEs) overcome antigen escape and heterogeneity across multiple epithelial carcinomas in preclinical models, achieving complete tumor eradication where conventional single-target CAR T cell therapies often failed, supporting broad translational potential for solid tumor immunotherapy.